Regenerative Medicine Cluster Initiative in BC
A UBC Research Excellence Cluster

WIP Seminar Series, Dr. Kevin Hay

WIP Seminar Series, Dr. Kevin Hay

February 14, 2019 @ 4:00 pm – 5:00 pm
Diamond Lecture Theatre, BCCRC
675 West 10th Avenue

Dr. Kevin Hay, Clinician Scientist, Terry Fox Laboratory & Leukemia/Bone Marrow Transplant Program of BC, Assistant Professor, Department of Medicine, UBC is speaking at the Diamond Lecture Theatre at the BCCRC February 14th, 2019.

Multi-antigen targeting CAR-T therapy for acute myeloid leukemia

Acute myeloid leukemia (AML) is an aggressive, clonally heterogeneous malignancy of hematopoietic precursors for which few therapeutic options exist. Adults with relapsed/refractory AML have a dismal prognosis, highlighting the urgent need for novel therapeutics. Cellular immunotherapy with chimeric antigen receptor (CAR-)T cells has demonstrated impressive results in the treatment of B cell malignancies, with remission rates as high as 85%. Spurred by these results, we are developing CAR-T cells targeting AML. I will discuss the challenges of translating this therapy from B cell malignancies to AML, including target antigens, potential toxicity, and the advantage of using a multi-antigen approach.

Back to Calendar